Data as of Dec 19
| +0.15 / +1.90%|
The 3 analysts offering 12-month price forecasts for Amicus Therapeutics Inc have a median target of 9.00, with a high estimate of 14.00 and a low estimate of 9.00. The median estimate represents a +12.08% increase from the last price of 8.03.
The current consensus among 3 polled investment analysts is to Buy stock in Amicus Therapeutics Inc. This rating has held steady since December, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.